| «« | September 2024 | »» |
Mon
Tue
Wed
Thu
Fri
Sat
Sun
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Newsletter
Project Name :
Phase 2b (Evaluate the Efficacy and safety of 2 Fixed Doses (0,5 mg or 2,5 mg of MIN-117 in Adult Patients with Major depressive Disorders)
Donor Organization :
Minerva Neuroscience
Budget:
შესრულების შესაბამისი
Grant number :
MIN-117C03
Direction :
8 Medical Sciences
Subdirection :
8-317 Psychiatrics
Key word :
Phase 2b, Major Depressive Disorders,
Description :
research of MIN-117 (5 mg and 2,5 mg) in Major Depressive Disorders. Phase 2b
Duration :
09/01/2018 - up to date
Leader :
David Zurabashvili
Project manager :
Project participant(s) :
If there are some problems please send
Message to administrator
